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Dynamic contrast agent-enhanced magnetic resonance imaging measurements of the perfusion of an immunogenic murine tumour
showed that immune rejection was preceded by an increase in the apparent vascular volume of the tumour. This increase in
vascularity, which has been observed previously in other tumours undergoing immune rejection, was confirmed by histological
analysis of tumour sections obtained postmortem. Magnetic resonance imaging measurements similar to this could be used in the
clinic to monitor the early responses of tumours to immunotherapy, before there is any change in tumour growth rate or volume.
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The early detection of tumour responses to therapy will be valuable
both in the development of new therapies and in their subsequent
implementation in the clinic, where early response detection could
be used to tailor therapy to individual patients.
The most widely used criterion for tumour response has been
tumour shrinkage, however with some therapies, and particularly
during early stage clinical trials, tumours may show a positive
response to therapy in the absence of any change in tumour
volume. For example, the antivascular drug combretastatin can
produce dramatic changes in tumour blood flow without
significantly affecting tumour volume (Chaplin et al, 1999).
Magnetic resonance imaging (MRI) is widely used in the clinic
for tumour detection and for monitoring tumour shrinkage post-
therapy. Dynamic MRI measurements of contrast agent inflow into
tumour vasculature and interstitial space, following intravenous
injection of the agent, can both enhance the sensitivity of tumour
detection as well as giving information on vascular volume and
permeability (Tofts, 1997). Such measurements were used in the
recently completed Phase I clinical trials of combretastatin to
detect changes in tumour blood flow following drug treatment
(Galbraith et al, 2000; Dowlati et al, 2002). These measurements
are part of a growing family of so-called ‘molecular imaging’
methods in which specific molecules, which report on some aspect
of tissue biochemistry or physiology, are detected through the
changes that they produce in image contrast. In this case, the
image was created by MR; however, molecular probes have also
been developed for optical and radiological detection (Weissleder,
2001; Weis[43]sleder and Mahmood, 2001). The probes thus
identify, amplify and translate information about underlying tissue
biochemistry and physiology into the image. These techniques can
be used in the laboratory, for basic science studies, and in the
clinic, where they can provide specific information about
responses to therapy. For example, in the case of MRI, contrast
agents have been developed for imaging pH (Zhang et al, 1999;
Aime et al, 2002), for monitoring gene expression (Louie et al,
2000; Weissleder et al, 2000), for detecting angiogenic tumour
vasculature (Sipkins et al, 1998) and for detecting tumour cell
apoptosis following chemotherapy (Zhao et al, 2001).
Tumour immunotherapy has, until recently, met with limited
success. However, a better understanding of how cytotoxic T
lymphocytes respond to tumour cells, the molecular signalling
pathways that regulate responsiveness and the mechanisms by which
tumours evade immune surveillance coupled with the identification
of tumour antigens has led to renewed interest in this therapeutic
approach (Rosenberg, 2001; Smyth et al, 2001; Pardoll, 2002).
Indeed, there are many examples of immunotherapies that are
currently in clinical trials (http://www.cancer.gov/clinical_trials).
We show here how dynamic contrast agent-enhanced MRI
(DCE-MRI) measurements can be used to detect changes in the
vascularity of tumours undergoing immune rejection, prior to a
reduction in tumour volume. We suggest that similar measure-
ments could be used clinically to detect the early response of
tumours to immunotherapy.
MATERIALS AND METHODS
Antibodies and other reagents
Rabbit antiovalbumin antibody was purchased from Research
Diagnostics Inc., NJ, USA. Rabbit polyclonal antibodies recognising
CD4, CD8-a, goat polyclonal antibodies recognising CD-68
(M-20) and a secondary anti-rabbit IgG staining system (‘Immuno-
Cruz staining system’) were purchased from Santa Cruz Biotechnol-
ogy Inc., USA. Rabbit anti-human Factor VIII antibody was
purchased from DAKO, Copenhagen, Denmark. Fluorescein iso-
thiocyanate (FITC)-conjugated monoclonal antibodies recognising
rabbit and goat IgGs were purchased from Sigma (Gillingham,
Dorset, UK). All other reagents were of analytical grade.
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sCell lines and tumour implantation
The E.G7-OVA cell line was originally derived from the murine
thymoma line, EL-4, by transfection with a neomycin-selectable
vector expressing full-length chicken ovalbumin (Moore et al,
1988). E.G7-OVA and EL-4 cells used in this study were taken from
frozen stocks held at GlaxoSmithKline, Stevenage, UK and were
originally obtained from Francis Carbone (Scripps Clinic, La Jolla,
CA). They were cultured as a suspension in RPMI 1640 medium
(Invitrogen Ltd, Paisley, UK) containing 10% heat-inactivated
foetal calf serum (PAA Laboratories, GmbH Linz, Austria), 2mML -
glutamine, penicillin (100unitsml
 1) and streptomycin
(100mgml
 1). Selection of E.G7-OVA cells was maintained using
culture medium containing 400mgml
 1 G418.
Female C57BL/6 mice were purchased at 6–8 weeks of age from
Charles River Ltd (UK). Tumour cells (5 10
6) were injected
subcutaneously into the shaved flanks of mice. Tumour size was
measured using calipers and is reported as the product of the two
largest perpendicular diameters (mm
2). All experiments were
conducted in compliance with a project licence issued under the
Animals (Scientific Procedures) Act 1986 and were designed with
reference to the UKCCCR guidelines for the welfare of animals in
experimental neoplasia. The work was approved by a local ethical
review committee.
Tumour histology and immunohistochemical examination
Tumours were fixed in 10% formalin and embedded in paraffin.
Five-micrometre thick sections were cut and stained with
haematoxylin and eosin (H&E) or Masson’s trichrome stain
(Sigma). For immunoperoxidase staining, the rabbit primary
antibodies were detected using a biotinylated anti-rabbit IgG
secondary antibody and horseradish peroxidase (HRP)-conjugated
to streptavidin using the Immuno-Cruz staining system. The
formalin-fixed and paraffin-embedded sections were deparaffi-
nised and then heated to 951C for 10min in 10mM sodium citrate
buffer, pH 6.0. They were then incubated with a peroxidase- and
then a serum-block and incubated with an appropriately diluted
primary antibody before incubation for 30min with the biotiny-
lated secondary antibody and 30min with the HRP–streptavidin
complex. The target protein was visualised by incubation for
30min with a peroxidase substrate, using diaminobenzidine
tetrahydrochloride (DAB) as the chromogen. As a negative control,
the sections were treated with nonimmune rabbit serum. For
immunofluorescence staining, the slides were prepared as
described for immunoperoxidase staining, except that the
peroxidase-block step was omitted. Slides were incubated with
an appropriately diluted primary antibody before detection with a
fluorescein-conjugated secondary antibody.
Flow cytometry was also performed on cell suspensions
prepared from tumour tissue and on the tumour cells grown in
culture. The cells were incubated with the appropriate primary
antibody and then with a secondary fluorochrome-conjugated
antibody. Flow cytometry was performed using a FACScan
Instrument and analysed with Lysys II software (Becton Dickinson,
Mountain View, CA, USA). Tumour cell suspensions were
prepared from tumour tissue by grinding the excised tumour
through a stainless-steel mesh (Dyall et al, 1999) into serum-free
RPMI 1640 medium.
Vascular volumes were analysed using an axial strip sampling
technique (Mayhew and Sharma, 1984). Sections, stained with
Masson’s trichrome stain or with antibody to Factor VIII, were
examined at  200 magnification and the images relayed to a
computer. The volume fraction occupied by the blood vessels was
estimated using a 486-point square lattice (18 27) with a field-of-
view of 0.209mm
2. Functional vessels were determined in a similar
manner following intravenous injection of carmine red dye
(Sigma) (Kimura et al, 1986). In these experiments, 1ml of a
saline solution containing 10% (wv
 1) carmine red dye and 5%
(wv
 1) gelatin were injected into the tail veins of anaesthetised
animals. The mice died within 30s of injection and were then
cooled below 41C for 1h in order to solidify the gelatin in the blood
vessels. The tumours were excised and fixed in a solution of 10%
formalin in saline. Sections (5mm thick) from the fixed and
paraffin-embedded tumours were then cut, deparaffinised and
counterstained in 2% light green dye (Sigma).
Determination of vascular endothelial growth factor levels
in serum, tumour cells and whole tumours
Vascular endothelial growth factor (VEGF) was detected by ELISA,
using an antibody raised against recombinant mouse VEGF and a
kit purchased from R&D Systems, Inc., Minneapolis, USA.
Information provided by the manufacturer indicates that this
antibody can be used to determine the relative mass values for
natural mouse VEGF. Serum was obtained from blood samples
taken by intracardiac puncture. The blood was allowed to clot for
30min before centrifugation for 10min at 1000g. The serum was
removed and either assayed immediately for VEGF or stored at
 851C until assayed. Vascular endothelial growth factor was
measured in tumour cells grown in culture by first harvesting cells
from a growing culture, washing them in ice-cold PBS and then
resuspending the cell pellet, containing approximately 2 10
8
cells, in 25ml of fresh extraction buffer in a tight-fitting Potter
homogeniser. The buffer contained 50mM Tris-HCl, pH 8.2, 2mM
dithiothreitol, 2mM EDTA and 1% Triton X-100. After 10 strokes
with the pestle, the resulting cell extracts were kept on ice for
30min and then centrifuged for 15min at 2000g, to remove any
insoluble material. The supernatants were removed and either
assayed immediately for VEGF or stored at  851C until assay.
Vascular endothelial growth factor levels in tumours were
measured by first preparing tumour homogenates. After weighing,
excised tumours were placed in 10ml of ice-cold extraction buffer
in a Potter homogeniser and homogenised using 25 strokes of the
pestle. The resulting homogenates were kept on ice for 30min and
then centrifuged for 15min at 2000g. The supernatants were
removed, passed through a 0.45mm Millipore filter and either
assayed immediately for VEGF or stored at  851C until assay.
Protein concentrations in the serum, cell and tumour extracts were
determined by the method of Bradford (1976), using a Bio-Rad
Protein Assay kit (Bio-Rad Laboratories, CA, USA).
Magnetic resonance imaging
Experiments were performed in a 9.4-T vertical bore (8.9cm
diameter) superconducting magnet (Oxford Instruments, Oxford,
UK), interfaced with a Varian Associates UnityPlus spectrometer
and Sun workstation running Vnmr 5.3B software. An unshielded
gradient set (Varian Associates) was used with a home-built probe
incorporating a two-turn surface coil probe (20mm diameter)
tunable to frequencies of 400MHz (
1H-imaging) and 162MHz
(
31P-spectroscopy), although only proton imaging was performed
in this study. Animals were anaesthetised by intraperitoneal (i.p.)
injection of Hypnorm/Hypnovel/dextrose–saline in the ratio
5:4:31 (10mlkg
 1 body weight) and immobilised in a cradle
that held the tumour in the centre of the surface coil. Hypnorm
was from Jansen Pharmaceuticals (High Wycombe, UK) and
Hypnovel was from Roche (Welwyn, UK). The dextrose–saline
solution contained 4% dextrose and 0.18% saline. Dextrose–saline
(0.5ml) was also given i.p. to reduce animal dehydration.
Anaesthesia was maintained, for up to 5h, with 1.75-h i.p.
injections of Hypnorm–dextrose–saline solution in the ratio
1:19 (5mlkg
 1 body weight). A flow of warm air was used to
maintain body temperature. Tumour perfusion was measured by
using a series of rapidly acquired T1-weighted spin echo images
(TE¼12.3ms, TR¼130ms) to monitor the inflow and subsequent
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sefflux from the tumour of the MRI contrast agent, gadolinium
diethylenetriaminepentaacetate (Gd-DTPA) (Magnevist, Schering),
as described previously (Beauregard et al, 1998, 2001). Gd-DTPA,
diluted to 40mM with sterile saline (0.9% sodium chloride), was
administered intravenously (i.v.) through a tail vein catheter over a
period of B30s to give 200mmolkg
 1 body weight. Images were
acquired immediately before and for up to 30min after contrast
agent injection from a 1mm-thick slice and a field-of-view of
20 20mm
2 over a 256 128 (phase encode) data matrix, that was
zero-filled to 256 256 data points. For calculation of the
paramagnetic contribution to the relaxation rate (R1p), an image
with TR¼3s was acquired at 30min after contrast agent injection.
Image pixel intensities in the short TR experiments were converted
to R1p values using the expressions derived by Kennedy et al
(1994). R1p is directly proportional to the concentration of the
contrast agent and can thus be used to assess quantitatively the
perfusion of a tumour by the contrast agent. These R1p maps
were transformed into maps of Gd-DTPA concentration, using the
relaxivity of Gd-DTPA at this field strength (3.88mM
 1s
 1)
(Thelwall et al, 2001). The procedure detailed by Su et al (1994),
which enables separation of the vascular and extravascular
components, was then applied and the vascular volumes of the
tumours determined. In doing this, the data of Furman-Haran et al
(1996) were used to derive the arterial input function, where a
biexponential function characterises the plasma concentration of
Gd-DTPA in mice after i.v. injection. Perfusion can also be
assessed in a semiquantitative manner by measuring signal
enhancement in the presence of the contrast agent. The enhance-
ment of signal intensity in the tumours following contrast agent
injection was calculated, on a pixel-by-pixel basis, by subtracting
pixel intensities in the precontrast images from the intensities of
the corresponding pixels in the postcontrast images and then
dividing by the pixel intensities in the precontrast images.
A further estimate of vascular volume was made using the
macromolecular contrast agent, BSA–Gd-DTPA, in which bovine
serum albumin (BSA) is conjugated to Gd-DTPA. The agent was
prepared as described by Ogan et al (1987) and injected i.v. to give
a concentration of 250mgkg
 1 body weight. The imaging protocol
was the same as that used for the Gd-DTPA experiment except that
a long-TR image was not acquired and therefore only signal
enhancement after contrast agent injection was calculated.
RESULTS
Tumour model
The E.G7-OVA thymoma, a derivative of the H-2
b thymoma EL-4,
which has been transfected with a vector expressing a full-length
chicken ovalbumin cDNA (Moore et al, 1988) and displays the
immunodominant epitope of chicken ovalbumin on its surface
(Shastri and Gonzalez, 1993), has been a relatively widely used
model in studies of immune responses to tumour cells (Zhou et al,
1992; Minev et al, 1994; Brossart et al, 1997). The doubling times
for the EL-4 and E.G7-OVA tumour cells in vitro were 11.070.1
(s.e.m., n¼3) and 11.9970.4 (s.e.m., n¼3) h, respectively. The
small difference in these doubling times is not statistically
significant. Following subcutaneous injection of 5 10
6 EL-4 or
E.G7-OVA cells, C57BL/6 mice developed palpable tumours within
5 days (Figure 1). There were no significant differences in the
growth rate of EL-4 tumours (n¼30) and of those E.G7.OVA
tumours that arose from cells that had been implanted between
nominal passage numbers 13–20 (n¼28). However, E.G7-OVA
tumours that arose from cells that had been implanted between
nominal passage numbers 7–12 grew more slowly than EL-4
tumours and those E.G7-OVA tumours that arose from cells
implanted between the later nominal passage numbers 13–20
(Po0.001, ANOVA). Twenty-three out of 73 (32%) E.G7-OVA
tumours underwent spontaneous regression, including 18 out of 42
(43%) that developed from cells implanted between nominal
passage numbers 7–12 and five out of 26 (19%) that developed
from cells implanted between nominal passage numbers 13–20.
This difference in the tumorigenicity of early and late passage cells
was judged to be significant by a c
2 test (c
2¼5.9, Po0.025).
Flow cytometry showed that an earlier passage of the E.G7-OVA
cell line (nominal passage number 10) expressed significantly
(Po0.01) higher levels of ovalbumin (842795, mean7s.e., n¼3)
when compared to a later passage (402751, mean7s.e., n¼3)
(nominal passage number 13). The EL-4 cell line showed no
significant detectable signal (3.070.1, mean7s.e., n¼3). The
numbers represent fluorescence intensity in arbitrary units.
Immunohistochemistry showed significant staining for ovalbumin
in sections of E.G7-OVA tumours, but no detectable staining in
sections of EL-4 tumours (data not shown). Flow cytometric
analysis of ovalbumin expression on cells prepared from
disaggregated tumours showed that ovalbumin expression was
significantly higher in regressing E.G7-OVA tumours than in those
that continued to grow (Table 1).
Tumour histology
Previous work has shown that CD8
+ T cells are responsible for
rejection of E.G7-OVA tumours and that administration of an anti-
CD4 monoclonal antibody, that mediates regression of established
E.G7-OVA tumours, leads to increased infiltration of CD8
+ cells
0
50
100
150
200
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Figure 1 Growth rates of implanted tumours following subcutaneous
injection of 5 10
6cells at t¼0 days. (K) EL-4 tumours (n¼30); (’)
E.G7-OVA tumours, arising from cells implanted at nominal passage
numbers 13 – 20 (n¼28); (m) E.G7-OVA tumours arising from cells
implanted at nominal passage numbers 7 – 12 (n¼26); (~) regressive
E.G7-OVA tumours (18 arising from cells implanted at nominal passage
numbers 7 – 12 and five arising from cells implanted at nominal passage
numbers 13 – 20). The symbols represent the mean7s.e.m. of the
volumes reported as the product of the two largest perpendicular
diameters. Where they are not visible, the error bars lie within the symbols.
Table 1 Flow cytometric analysis of ovalbumin expression and immune
cell infiltration in EL-4 , progressive E.G7-OVA and regressive E.G7-OVA
tumours
Tumour type
Antigen EL-4
E.G7-OVA
(regressive)
E.G7-OVA
(progressive)
Ovalbumin 3.470.2 16087480
a 309766
CD8 150723 272727
a 174719
CD68 64717 177735
b 99729
At 13 days after implantation, single-cell suspensions were prepared by disaggregating
solid tumour material. These cell suspensions were then incubated with the relevant
primary antibody and fluorochrome-conjugated secondary antibody, as described in
the Materials and Methods section. Three tumours were used in each group and the
numbers represent the mean7s.e.m. of the fluorescence intensities in arbitrary units.
aStatistically significantly different from EL-4 and progressive E.G7-OVA tumours,
Po0.01;
bstatistically significantly different from EL-4 tumours, Po0.01.
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s(Vasovic et al, 1997; Dyall et al, 1999). Flow cytometric analysis of
disaggregated tumours showed that there was increased numbers
of CD8
+ and CD68
+ cells in regressing E.G7-OVA tumours when
compared to EL-4 tumours and progressive E.G7-OVA tumours
(Table 1). CD68 is antigen expressed on murine macrophages
(Ramprasad et al, 1995). The increased infiltration of CD8
+ cells
and macrophages was confirmed by immunohistochemistry (data
not shown).
The levels of VEGF in the serum of EL-4 and E.G7-OVA tumour-
bearing mice, in EL-4 and E.G7-OVA tumour homogenates and in
extracts of EL-4 and E.G7-OVA tumour cells grown in vitro were
measured by ELISA (see Materials and Methods section). Vascular
endothelial growth factor was significantly higher (Po0.01) in the
serum of tumour-bearing mice (18.671.0pgml
 1, E.G7-OVA;
18.471.3pgml
 1, EL-4) than in controls (9.271.1pgml
 1). There
were two mice in each group and four measurements of VEGF per
group. There were also significantly higher (Po0.01) levels of
VEGF in E.G7-OVA tumour homogenates (16.970.4pgmg
 1
protein) than in EL-4 tumour homogenates (12.570.5pgmg
 1
protein) (two mice in each group and four measurements per
group). The E.G7-OVA tumours arose from cells implanted at
nominal passage 12 and were taken for extraction 13 days after
tumour cell implantation. There was no significant difference in
the levels of VEGF in extracts of E.G7-OVA and EL-4 cells, 4.870.6
and 5.370.2pgmg
 1 protein, respectively.
In addition to the lymphocytic infiltrate observed in regressing
E.G7-OVA tumours, there was also clear evidence of an
angiofibroblastic response (Bodurtha et al, 1976; Lynch et al,
1978; Martin et al, 1987; Shaw et al, 1989; Vaage, 1992), with
proliferation of fibroblasts and capillary vessels and encapsulation
of the tumour in a fibrous, collagen containing, capsule (see
Figure 2). Fibrous tissue and stroma stain bluish-green, and blood
vessels containing red cells stain red. The functional vascular
volume, as assessed from carmine dye injection (see Materials and
Methods section), was significantly increased in regressing E.G7-
OVA tumours as compared to progressive E.G7-OVA tumours and
EL-4 tumours (see Table 2). The dye was injected and the tumours
excised between days 13 and 15, at which times the regressing
E.G7-OVA tumours could be identified by cessation of tumour
growth or even by a small reduction in size (see Figure 1). The
increased vascular volume was confirmed in sections stained with
an antibody that recognises Factor VIII on vascular endothelial
cells and in sections stained with Masson’s trichrome (Table 2).
Magnetic resonance imaging
Perfusion of EL-4 and E.G7-OVA tumours was assessed by
monitoring the inflow of an MRI contrast agent, Gd-DTPA,
following intravenous injection between days 10 and 12 after
tumour implantation. The inflow of the agent was measured using
a series of rapidly acquired, T1-weighted, spin echo images, in
which the increase in signal intensity was proportional to the
concentration of the contrast agent. Typical image series for an
EL-4 tumour and an E.G7-OVA tumour, which went on to regress,
are shown in Figure 3. The increased signal intensity in the
Figure 2 Histological features of spontaneous regression in E.G7-OVA tumours. Tumour sections (5mm thick) were stained with Masson’s trichrome (A)
or carmine red dye counterstained with light green (B). In A (ii and iii) the tumour cells can be seen to be surrounded by fibroblasts and capillaries filled with
red blood cells (arrowed). There is also evidence of collagen deposition, which stains green with this dye (arrowed in A iii). A(i) is a representative section
from an EL-4 tumour. The tumour sections shown in B (ii and iii) were obtained following injection of the animal with carmine dye. Functional vessels are
stained red in these sections (arrowed). B(i) is a representative section from an EL-4 tumour. The bars are 400mm long.
Table 2 Vascular volumes in EL-4, progressive E.G7-OVA and regressive
E.G7-OVA tumours
Tumour type
Stain EL-4
E.G7-OVA
(regressive)
E.G7-OVA
(progressive)
Masson’s trichrome 0.971.5 8.775.5
a 1.171.6
Carmine red 0.771.2 8.975.3
a 1.171.7
Factor VIII 0.771.4 6.174.0
a 0.871.2
DCE MRI (Gd-DTPA) 2.171.2 8.972.7
a 4.471.4
b
Tumour sections stained with either Masson’s trichrome or an antibody against
Factor VIII, or obtained from mice that had been injected with carmine red dye, were
observed at  200 magnification and the resulting images relayed to a computer
screen. Vascular volume, as a percentage of tumour volume, was estimated by an
axial strip sampling technique, as described in the Materials and Methods section. The
data are the mean percentage7s.d. for 90 tumour areas stained with Masson’s
trichrome, 30 areas stained with antibody against Factor VIII and 90 areas from
carmine dye-injected tumours. Three tumours were used in each group. Also given
are vascular volumes (as mean percentage7s.d.) determined using dynamic contrast
agent-enhanced MRI, as described in the Materials and Methods section. Respectively,
three, five and five tumours were used.
aStatistically significantly different from EL-4
and progressive E.G7-OVA tumours, Po0.01.
bStatistically significantly different from
progressive E.G7-OVA tumours, Po0.05.
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sregressive E.G7-OVA tumour (Figure 3A) shows clear evidence of
vascular proliferation in the tumour periphery. Histological
analysis also showed that the vascular proliferation accompanying
immune rejection occurred predominantly at the tumour edge
(data not shown). These MR images show, in a qualitative way, that
tumour perfusion was increased in the E.G7-OVA tumour that
went on to regress, when compared to the nonregressing EL-4
tumour. This was confirmed, in a more quantitative way, by
plotting mean signal enhancement across the whole tumour vs
time, for 5 EL-4, 5 E.G7-OVA progressive and 5 E.G7-OVA
regressive tumours (Figure 4). Signal enhancement in the
regressive E.G7-OVA tumours was significantly greater
(Po0.0001, one way ANOVA) than in either the EL-4 or
progressive E.G7-OVA tumours. These data can be used to
estimate perfusion quantitatively by converting the increase in
image pixel intensities, in the presence of the agent, into R1p
values, as described previously (Kennedy et al, 1994; Beauregard
et al, 1998, 2001) and in Materials and Methods section. R1p is the
paramagnetic contribution to the longitudinal relaxation rate and
is directly proportional to the concentration of the contrast agent.
The centres of these tumours were relatively poorly perfused and
therefore estimates of R1p values in these regions had a large error
associated with them, as we have observed previously in other
tumours (Beauregard et al, 2001, 2002). Therefore, perfusion was
assessed by measuring the mean increase in R1p values in a 20
pixel-wide band in the tumour periphery. Plots of the mean
increase in R1p values, following intravenous injection of
Gd-DTPA, in EL-4, progressive E.G7-OVA and regressive E.G7-
OVA tumours, are shown in Figure 4. These show that there was a
significant (Po0.001, n¼5, ANOVA) increase in the perfusion of
those E.G7-OVA tumours that went on to regress, when compared
to EL-4 and progressive E.G7-OVA tumours. These data were also
analysed to estimate tumour vascular volumes, using the model
described by Su et al (1994). The pharmacokinetic data of Furman-
Haran et al (1996) for Gd-DTPA in mouse plasma were used to
derive an arterial input function. The vascular volumes of
regressive E.G7-OVA tumours were significantly higher than those
of both EL-4 (Po0.01) and progressive E,G7-OVA tumours
(Po0.01, Student’s t-test). The vascular volumes of the progressive
E.G7-OVA tumours were also significantly higher than those of EL-
4 tumours (Po0.05). The vascular volumes determined by MRI
were similar to those obtained using the carmine dye injection
technique for the regressive EG7-OVA tumours, but significantly
higher than those obtained using the dye in the EL-4 and
progressive E.G7-OVA tumours (see Table 2). This may reflect
the fact that the MRI estimate was taken from the tumour
periphery, where vessel density is higher.
The high molecular weight contrast agent, BSA–Gd-DTPA, was
also used to determine relative vascular volumes for the three
tumour models. This contrast agent is initially contained in the
plasma compartment, so allowing an estimate of vascular volume.
In areas of permeable vasculature it then escapes into the
interstitial space. The signal enhancement for the three tumours
(Figure 5) indicates that the vascular volume of regressive E.G7-
OVA was greater than that of the other two tumour models,
in agreement with the quantitative estimates obtained using
A
B
Figure 3 A series of T1-weighted MR images acquired from a regressive E.G7-OVA tumour (A) and an EL-4 tumour (B) following i.v. injection of the MRI
contrast agent, Gd-DTPA. The first images in the series were acquired prior to contrast agent injection. The subsequent images (reading from left-to-right
and top-to-bottom) were acquired at 2min intervals. The presence of the contrast agent increases signal intensity in the images and these increases are
proportional to its concentration.
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sGd-DTPA and from histology. The increase in signal enhancement
with time observed for regressive E.G7-OVA tumours (Figure 5)
indicates a more permeable vasculature than in the EL-4 or
progressive E.G7-OVA tumours.
DISCUSSION
The clinical development of cytotoxic antitumour drugs has
traditionally viewed tumour shrinkage as an objective indicator
of drug efficacy. However, early Phase I/II clinical trials of
antiangiogenic drugs have shown that they are mostly cytostatic,
slowing or stopping tumour growth, without producing tumour
regression. This has prompted the recommendation that in early
stages of antiangiogenic drug development, we should seek to
establish surrogate markers of drug efficacy (Cristofanilli et al,
2002). Since cytostasis is a reasonable outcome, in the first
instance, and since we might reasonably expect to observe this
during the development of other therapeutics, then perhaps this
recommendation should be widened to include other therapeutic
approaches. We have shown here how clinically applicable,
noninvasive DCE MRI measurements of tumour perfusion can
be used to detect the relatively early signs of tumour immune
rejection, before there is a reduction in tumour growth rate or
volume.
The E.G7-OVA tumour model has been widely used in studies of
tumour immunotherapy procedures (Zhou et al, 1992; Minev et al,
1994; Brossart et al, 1997). The cell line, which has been transfected
with a vector expressing full-length chicken ovalbumin cDNA,
expresses on its surface an eight-residue peptide of ovalbumin in
association with the MHC class I molecule H-2K
b. Adoptive
transfer experiments have demonstrated that OVA-specific CD8
+ T
cells can specifically protect animals against the growth of E.G7-
OVA tumours, but that they cannot eradicate established tumours.
Tumour eradication can be obtained, however, by injection of an
antibody against CD4, which is expressed on E.G7-OVA cells in
vivo (Vasovic et al, 1997). The antibody-mediated tumour
rejection was shown to have an absolute requirement for CD8
+ T
cells and CD11b
+ (phagocytic) cells. Rejection was accompanied by
significant infiltration of CD8
+ T cells, which was approximately
five times greater than in control tumours (Dyall et al, 1999).
In the E.G7-OVA tumour model used in this study, we noted a
significant level of spontaneous regression, which appeared to be
correlated with the level of ovalbumin expression determined by
flow cytometry. Tumours arising from early passage cells, which
showed the highest levels of ovalbumin, underwent spontaneous
regression with a significantly higher frequency (Po0.025) than
tumours arising from later passage cells, which showed lower
levels of ovalbumin (Figure 1). Tumour regression was accom-
panied by increased infiltration of CD8
+ T cells, which was nearly
double that in EL-4 tumours, and of macrophages (CD68
+)
(Table 1). What the antiovalbumin antibody is recognising on
the surface of these E.G7-OVA cells and the factors responsible for
the decrease in expression of the recognised epitope with cell
passage number are not clear. Nevertheless, this tumour provided
us with a model system in which we could evaluate MRI methods
for detecting early signs of tumour rejection and thus methods for
evaluating the early responses of tumours to immunotherapy.
Measurements of tumour perfusion showed that this was
significantly increased in those E.G7-OVA tumours that went onto
regress when compared to the EL-4 parent tumour and progressive
E.G7-OVA tumours. Tumour perfusion was assessed by monitor-
ing the inflow of an intravenously injected MRI contrast agent,
Gd-DTPA, using a series of rapidly acquired T1-weigthed spin echo
images (Figure 3). The presence of the contrast agent leads to
signal enhancement in these images. The kinetics of signal
enhancement were analysed using a pharmacokinetic model to
obtain a vascular volume, as described by Su et al (1994). The
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Figure 4 Time-dependent changes in signal enhancement (A) and R1p
values (B) in dynamic contrast agent-enhanced T1-weighted images
obtained from EL-4 (m), progressive E.G7-OVA (’) and regressive
E.G7-OVA (K) tumours. R1p, the paramagnetic contribution to the
relaxation rate, is equivalent to the contrast agent concentration. The
symbols represent the mean7s.e.m. (n¼5). The numbers for signal
enhancement were obtained from the entire tumour cross-section.
However, because of difficulties in estimating R1p values in the relatively
poorly perfused regions in the centres of some tumours, these were
calculated for a 20 pixel-wide band in the tumour peripheries, where vessel
density was higher.
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Figure 5 Time-dependent changes in signal enhancement in tumours
using dynamic contrast-enhanced MRI with the macromolecular contrast
BSA–Gd-DTPA. A series of T1-weighted spin echo images were acquired
from EL-4 (m, n¼7), progressive E.G7-OVA (’, n¼6) and regressive
E.G7-OVA (K, n¼2) tumours. The symbols and error bars show the
mean7s.e.m. The values were calculated for a 20 pixel-wide band in the
tumour peripheries, where vessel density was higher. The high molecular
weight agent is initially confined to the vasculature, so the greater signal
enhancement of regressive E.G7-OVA tumours is indicative of a higher
functional vascular volume fraction.
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was attributed in this model to vascular distribution. However, Gd-
DTPA is a relatively small molecule and can leak rapidly out of the
vasculature into the tumour interstitial space. Therefore, the
vascular volume estimated using this model is an apparent volume,
which includes the true vascular volume and a fast leakage volume.
Nevertheless, there was a reasonable agreement between the
vascular volume determined in this way for the regressive E.G7-
OVA tumours and that determined by conventional histological
methods in tumour sections obtained post mortem. The latter
included determination of functional vascular volume using
carmine dye injection, detection of intravascular red cells using
Masson’s trichrome stain, and staining of vascular endothelial cells
using antibody against Factor VIII. The higher vascular volume
determined by MRI in the EL-4 and progressive E.G7-OVA
tumours may be a reflection of the fact that the MRI measurements
were taken from the tumour periphery, where vessel density was
higher.
The vascular proliferation observed here in regressing E.G7-
OVA tumours has been observed previously during the sponta-
neous regression of melanoma (Bodurtha et al, 1976; Lynch et al,
1978; Shaw et al, 1989; Blessing and McLaren, 1992) and in other
tumours (Junker et al, 1997). In melanoma, Shaw et al (1989)
defined three stages of regression; early, in which there was
lymphocytic infiltration and ‘degenerating’ tumour cells; inter-
mediate, in which there were areas of proliferating fibroblasts
associated with new blood vessels, and late, in which there was an
absence of tumour cells and extensive fibrosis. It seems clear that,
on this histopathological scale, our MRI measurements are
detecting intermediate stages of immune rejection. The histological
measurements, which were made on tumours excised 2–3 days
after the MRI measurements, when evidence of tumour regression
was apparent from cessation of tumour growth or a reduction in
size, also showed evidence of later stages of regression. This
included extensive fibrosis and also the presence of a collagen
capsule surrounding tumour cells. The capsule appears to be laid
down by infiltrating macrophages (Vaage and Harlos, 1991). The
vascular proliferation may have been stimulated by angiogenic
growth factors secreted by the infiltrating macrophages (Leek et al,
1996). Extracts prepared from tumours arising from early passage
cells and excised 13 days after implantation, when there was
evidence that they had ceased growth and were thus classified as
regressive tumours, showed significantly higher levels of VEGF
when compared to extracts of EL-4 tumours. Vascular endothelial
growth factor is known to increase vascular permeability, and
therefore the elevated levels in regressive E.G7-OVA tumours
might explain the increased vessel permeability observed in the
MRI experiments in which BSA–Gd-DTPA was used as the
contrast agent (Figure 5). The serum of tumour-bearing mice also
contained significantly higher levels of VEGF than serum from
nontumour-bearing control animals, as has been observed
previously in tumour-bearing animal and human subjects (Kondo
et al, 1994).
The observation that tumour regression is preceded by an
increase in vascular volume is at variance with an MRI study of
allogeneic tumours in rat, where a decrease in tumour volume was
shown to be preceded by a reduction in vascular volume (Su et al,
2000). However, there was no accompanying histology in the rat
study and it is difficult to know at what stage of regression these
tumours were at when studied by MRI. The differences between
these studies might be resolved by extending, to earlier time
points, measurements of contrast agent uptake in the E.G7-OVA
tumours. However, this will be difficult because of their relatively
small size at these earlier time points.
Detection of earlier signs of impending regression might be
possible by monitoring CD8
+ T-cell infiltration. Adoptive transfer
experiments have shown that control of E.G7-OVA tumour growth
depends on retention of CD8
+ T cells within the tumour. Tumour
growth continued when the cells migrated out of the tumour into
the spleen and draining lymph nodes (Shrikant and Mescher,
1999). Magnetic resonance imaging detection of immune cell
infiltration of a tissue can be accomplished by labelling the
immune cells with MR-detectable paramagnetic agents. Using this
technique, immune cell infiltration has been detected in the
pancreas of an animal model of Type I diabetes (Moore et al,
2002). Whether similar experiments will be feasible in a clinical
context remains to be determined.
In conclusion, we have demonstrated a noninvasive MRI
method that, by detecting the vascular proliferation that precedes
immune rejection, can be used to detect the early signs of this
process. We propose that DCE-MRI could be used in the clinic to
evaluate early tumour responses to immunotherapy. This will,
however, require its evaluation in other preclinical models of
tumour immune rejection in order to establish the generality of
this vascular response. Consideration will also have to be given to
selection of the most appropriate pharmacokinetic model used to
derive the vascular parameters. An additional complication arises
from the fact that tumour perfusion is often grossly heterogeneous
and can vary considerably between different tumour types.
Therefore, in the clinic DCE-MRI measurements would need to
be carried out immediately before and in the days following
administration of immunotherapy. While this might require
several imaging sessions, this is nevertheless more practical than
trying to measure reduction in tumour volume and, more
importantly, may give an earlier indication of response.
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